RedHill Announces MHRA Acceptance of Clinical Trial Application for Phase III clinical trial of RHB-104 in Crohn’s Disease

RedHill Announces MHRA Acceptance of Clinical Trial Application for Phase III clinical trial of RHB-104 in Crohn’s Disease
RedHill Biopharma Ltd., an emerging biopharmaceutical company based in Israel focused on the development of small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, recently announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted the company’s Clinical Trial Application (CTA) to begin a second Phase III clinical trial of RHB-104

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *